Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 was 円357,386 Mil.
Chugai Pharmaceutical Co's quarterly Total Liabilities
increased
from Sep. 2025 (円293,481.00 Mil) to Dec. 2025 (円442,863.00 Mil) but then
declined
from Dec. 2025 (円442,863.00 Mil) to Mar. 2026 (円357,386.00 Mil).
Chugai Pharmaceutical Co's annual Total Liabilities
declined
from Dec. 2023 (円306,967.00 Mil) to Dec. 2024 (円306,874.00 Mil) but then
increased
from Dec. 2024 (円306,874.00 Mil) to Dec. 2025 (円442,863.00 Mil).
Chugai Pharmaceutical Co Total Liabilities Related Terms
Chugai Pharmaceutical Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Chugai Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of 円357,386 Mil mean?
Chugai Pharmaceutical Co (TSE:4519) has a Total Liabilities of 円357,386 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Total Liabilities too high?
Chugai Pharmaceutical Co's current Total Liabilities is 円357,386 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Total Liabilities compare to LLY and JNJ?
Chugai Pharmaceutical Co's Total Liabilities of 円357,386 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Total Liabilities is 円357,386 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,749.68, compared to a current price of 円7,325.00 — trading 5.5% below its estimated fair value. The current Total Liabilities is 円357,386 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current Total Liabilities is 円357,386 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,325.00 is trading 5.5% below its estimated GF Value™ of 円7,749.68.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
Total Liabilities: 円357,386 Mil
GF Value™: 円7,749.68 vs. price of 円7,325.00 (5.5% below fair value)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score
Get the complete analysis for TSE:4519
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
